Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer

2 Aug 2017

Abstract excerpt

The development of BH3 mimetics, which antagonize prosurvival proteins of the BCL-2 family, represents a potential breakthrough in cancer therapy. Targeting the prosurvival member MCL-1 has been an area of intense interest because it is frequently deregulated in cancer. In breast cancer, MCL-1 is often amplified, and high expression predicts poor patient outcome. We tested the MCL-1 inhibitor S63845 in breast...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Cancer therapeutics and mechanisms
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28768804
DOI: 10.1126/scitranslmed.aam7049

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancerPMID 28768804Read ↗

Toward Targeting Antiapoptotic MCL-1 for Cancer TherapySemantic proximity Read ↗

Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugsSemantic proximity Read ↗

Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivitySemantic proximity Read ↗

BH3 Mimetics in Hematologic MalignanciesSemantic proximity Read ↗

BH3 Mimetics for the Treatment of B-Cell Malignancies—Insights and Lessons from the ClinicSemantic proximity Read ↗

CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicitySemantic proximity Read ↗

Breast cancer dependence on MCL-1 is due to its canonical anti-apoptotic functionSemantic proximity Read ↗

The BCL2 family: from apoptosis mechanisms to new advances in targeted therapySemantic proximity Read ↗

Designed BH3 Peptides with High Affinity and Specificity for Targeting Mcl-1 in CellsSemantic proximity Read ↗

Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemiaSemantic proximity Read ↗

Mcl-1 inhibitors: a patent reviewSemantic proximity Read ↗

MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule InhibitorSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.